Clinical Trial

A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 9, 2024 (before its estimated May 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the efficacy and safety of concurrent chemoradiotherapy（CCRT）followed by cadonilimab（AK104) in high risk local advanced cervical cancer. Participants received CCRT，efficacy evaluation of CCRT was no disease progression who maintained with AK104（10.0 mg/kg，Q3W）until drug exposure over 1 years or disease progression or intolerable toxicity.
Trial Details
NCT Number NCT06251388
Lead Sponsor West China Second University Hospital
Collaborators: Affiliated Hospital of North Sichuan Medical College, The Affiliated Hospital Of Southwest Medical University
Conditions Cervical Cancer
Enrollment 50 participants
Start Date 2024-02-20
Primary Completion 2025-05-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2024-02-09